Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

U.S. and Canadian academics design novel prodrug approach to 5-FU chemotherapy

Sep. 10, 1999

Roche to submit sNDA for Xeloda as first-line colorectal cancer therapy

Sep. 10, 1999

Israeli group designs new family of nonpeptide, nonsulfhydryl Ras farnesylation inhibitors

Sep. 9, 1999

Atairgin and Washington State University to develop new therapeutic applications

Sep. 9, 1999

Roberts to market Fareston in the U.S.

Sep. 9, 1999

Full agenda for next week's Oncologic Drugs Advisory Committee meeting

Sep. 9, 1999

Topoisomerase poisons emerge from research at U.S. university

Sep. 9, 1999

RPR reports new naphthyl-piperazinone antitumor agents

Sep. 9, 1999

Kirin Brewery reports SAR in the area of Fas/FAP-1 binding inhibitors

Sep. 8, 1999

Onyx to initiate phase III trial with ONYX-015 in treatment of head and neck cancer

Sep. 8, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...